{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Malignancies", "query": { "condition": "Gastrointestinal Malignancies" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 7391, "total_pages": 740, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Malignancies&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-17T08:55:17.197Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05610163", "title": "Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Stage II Rectal Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Locally Advanced Rectal Adenocarcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Leucovorin calcium", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Long Course Chemoradiotherapy", "type": "RADIATION" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Sigmoidoscopy", "type": "PROCEDURE" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 760, "start_date": "2022-12-08", "completion_date": "2033-09-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-17T08:55:17.197Z", "location_count": 679, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 483 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05610163" }, { "nct_id": "NCT03436563", "title": "M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colon Adenocarcinoma", "High-Frequency Microsatellite Instability", "Metastatic Malignant Solid Neoplasm", "Rectal Adenocarcinoma", "Refractory Colorectal Carcinoma", "Stage IV Colon Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Rectal Cancer AJCC v8" ], "interventions": [ { "name": "Anti-PD-L1/TGFbetaRII Fusion Protein M7824", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-03-07", "completion_date": "2023-08-08", "has_results": true, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-09-17T08:55:17.197Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03436563" }, { "nct_id": "NCT02997228", "title": "Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Colorectal Adenocarcinoma", "Stage IV Colorectal Cancer AJCC v7" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2018-01-19", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-09-17T08:55:17.197Z", "location_count": 445, "location_summary": "Kingman, Arizona • Jonesboro, Arkansas • Anaheim, California + 346 more", "locations": [ { "city": "Kingman", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02997228" }, { "nct_id": "NCT02781012", "title": "Project Survival-Prospective Biomarker Discovery", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Neoplasms", "Pancreatic Cancer", "Pancreatitis", "Pancreatic Adenocarcinoma", "Metastatic Pancreatic Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Pancreatic Cancer Research Team", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 436, "start_date": "2016-03", "completion_date": "2022-02", "has_results": false, "last_update_posted_date": "2019-04-16", "last_synced_at": "2026-09-17T08:55:17.197Z", "location_count": 6, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Boston, Massachusetts + 3 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02781012" }, { "nct_id": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Carcinoma", "Adenoid Cystic Carcinoma", "Lung Cancer", "Non-Small Cell Lung Cancer", "Pancreatic Cancer", "Mesothelioma", "Esophageal Cancer", "Any Solid Tumors Progressed After a Prior Immunotherapy", "Head and Neck Squamous Cell Carcinoma", "Head and Neck Squamous Cell Carcinoma HNSCC", "Salivary Gland Carcinomas", "Head and Neck Cancers - Salivary Gland", "Head and Neck Cancers - Nasopharyngeal", "Head and Neck Cancers - Throat", "Small Cell Lung Cancer ( SCLC )", "Lung Cancer (Locally Advanced or Metastatic)", "Head and Neck Cancers - Tonsils", "Head and Neck Cancers Hypopharynx", "Head and Neck Cancers Larynx", "Head and Neck Cancers Lip", "Head and Neck Cancers Nasopharynx", "Head and Neck Cancers Oral Cavity", "Head and Neck Cancers", "Head and Neck Cancers Oropharynx", "Head and Neck Cancers Trachea" ], "interventions": [ { "name": "VMD-928 100 mg Tablet", "type": "DRUG" }, { "name": "VMD-928 Tablet and Pembrolizumab (200 mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VM Oncology, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 242, "start_date": "2018-06-08", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-09-17T08:55:17.197Z", "location_count": 14, "location_summary": "Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03556228" }, { "nct_id": "NCT00620607", "title": "huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stomach Neoplasms", "Metastatic or Locally Advanced Gastric Cancer", "Metastatic or Local Advanced GE Junction Cancer" ], "interventions": [ { "name": "huC242-DM4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunoGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2007-05", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2015-08-26", "last_synced_at": "2026-09-17T08:55:17.197Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Nashville, Tennessee • Houston, Texas + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00620607" }, { "nct_id": "NCT00985192", "title": "Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Translational Oncology Research International", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2009-09", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2020-08-05", "last_synced_at": "2026-09-17T08:55:17.197Z", "location_count": 18, "location_summary": "Alhambra, California • Bakersfield, California • Fullerton, California + 12 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00985192" }, { "nct_id": "NCT02031536", "title": "Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrinoma", "Glucagonoma", "Insulinoma", "Liver Metastases", "Pancreatic Polypeptide Tumor", "Recurrent Islet Cell Carcinoma", "Somatostatinoma" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2014-04-10", "completion_date": "2017-07-19", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-09-17T08:55:17.197Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02031536" }, { "nct_id": "NCT05874726", "title": "Biological Sample Repository for Gastrointestinal Disorders", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Obesity", "Obesity, Morbid", "Obesity, Primary", "Gastro-Intestinal Disorder", "Overweight and Obesity", "Overweight", "Overweight or Obesity", "Diabetes Type 2", "Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Hypertension", "Hyperlipidemias", "Sleep Apnea", "GERD", "Gastroesophageal Reflux", "Musculoskeletal Pain Disorder", "Cancer" ], "interventions": [ { "name": "Blood Collection", "type": "DIAGNOSTIC_TEST" }, { "name": "Urine Collection", "type": "DIAGNOSTIC_TEST" }, { "name": "Tissue Sample Collection", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Pichamol Jirapinyo, MD, MPH", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2023-07-19", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2025-12-02", "last_synced_at": "2026-09-17T08:55:17.197Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05874726" }, { "nct_id": "NCT07224568", "title": "Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor (Excluding CNS)", "Hepatocellular Carcinoma", "Liver Cell Carcinoma", "Liposarcoma", "Yolk Sac Tumor", "Rhabdomyosarcoma" ], "interventions": [ { "name": "SC-CAR.GPC3xIL15.21 CAR T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 21, "start_date": "2026-04-01", "completion_date": "2045-08", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-09-17T08:55:17.197Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224568" } ] }